New approaches to reduce the burden of RSV infection

Despite almost half a century of active research into the pathogenesis of respiratory syncytial virus (RSV)-induced acute and chronic airway disease, many questions remain unresolved. Experimental studies have demonstrated that interventions that reduced viral replication resulted in improvement of acute disease severity and long-term pulmonary abnormalities. The stage is ready for clinical studies to determine the potential benefit of new strategies for prevention and treatment of RSV infections.

Section editors:Gary Woodnutt – CovX, San Diego, USAPaul-Henri Lambert – Centre of Vaccinology, University of Geneva, Switzerland